Diabetic Health Quote
Private Health Insurance
Novo Nordisk Launches Diabetes Drug Victoza in China

Mon, 10 Oct 2011

Novo Nordisk's drug is now commercially available in China.

Victoza is a diabetes treatment option which effectively lowers blood sugar levels as well as weight with low risk of hypoglycaemia .

Victoza is now available in more than 39 countries worldwide.

Victoza is the first and only human glucagon-like peptide-1 (GLP-1) analogue which is 97% similar to endogenous human GLP-1. Like natural GLP-1, Victoza functions by stimulating the beta cells to release insulin only when blood sugar levels are high.

Due to this glucose-dependent mechanism of action, Victoza is linked with a low rate of hypoglycaemia.

In Europe Victoza is provided as treatment for type 2 diabetic adults to achieve glycaemic control.

In the USA, last January Victoza was approved as an addition treatment to and exercise to improve blood sugar control in adults with type 2 diabetes .
add to favouritesnewsletterlink to this pagesend to friendpost comments

Link to this page

Copy and Paste the following HTML into your page.

ContentMain
newsnews rss